You asked what the teen tirzepatide study actually found, so here is the short answer first. In a 72-week trial of 160 teens with obesity, published in JAMA on November 15, 2026, BMI fell 18.5% on tirzepatide and rose 0.5% on placebo. That 18.5% is a change in BMI, not in body weight. AJMC says tirzepatide is approved for obesity in adults, and the teen options it lists are different drugs.
Disclosure: For clarity, several links on this page are affiliate links. If you buy through them, this publication may earn a commission. Your price is the same either way.
Below you’ll find the results, the side effects the trial reported, who paid for it, and who to ask about your teen.
What did the tirzepatide teen trial find?
The study is called SURMOUNT-ADOLESCENTS. It is a phase 3, randomized, double-blind trial, and the full write-up is in the SURMOUNT-ADOLESCENTS paper in JAMA. (If you’re new to trial designs, understanding clinical study design (our research library) explains the terms.) Teens aged 12 to under 18 with obesity, or overweight with at least one obesity-related complication, were randomized 2:1. 109 got once-weekly tirzepatide plus a lifestyle intervention, and 51 got placebo. Doses were raised to a maximum tolerated dose of 5, 10 or 15 mg, according to AJMC. AJMC’s news summary, published November 17, 2026, reports the same numbers.
The main measure was BMI. Over 72 weeks, BMI fell 18.5% on tirzepatide and rose 0.5% on placebo. JAMA puts the gap between the groups at 19.0 percentage points (95% CI -23.9 to -14.1; P < .001). The body weight difference between the groups was -20.1 kg (95% CI -24.8 to -15.4). JAMA also says all 10 key secondary endpoints favored tirzepatide.
Tirzepatide vs placebo at week 72
| Measure | Tirzepatide | Placebo |
|---|---|---|
| Teens randomized | 109 | 51 |
| BMI change at week 72 | -18.5% | +0.5% |
| Reached at least 5% BMI reduction | 79.6% | 28.5% |
| Reached at least 20% BMI reduction | 48.1% | 7.9% |
| Fell below the 95th-percentile obesity threshold | 53.5% | 7.1% |
| Any adverse event | 95.4% | 82.4% |
| Gastrointestinal events | 81.5% | 54.9% |
| Vomiting | 50.9% | 13.7% |
| Nausea | 50.0% | 23.5% |
| Diarrhea | 45.4% | 25.5% |
| Stopped treatment for adverse events | 9.3% | 0% |
| Serious adverse events | 7.4% | 3.9% |
| Depression or suicidal ideation reported as an adverse event | 4.6% | 2.0% |
| Stopped treatment for any reason (JAMA) | 21% (23 of 109) | 31% (16 of 51) |
These percentages are reported by AJMC and JAMA. JAMA’s safety table counts 108 tirzepatide teens, because one participant left on the day of randomization and was excluded from the primary and safety analyses.
What side effects did the teens have?
Most of the side effects were in the stomach and gut. AJMC says gastrointestinal events happened in 81.5% of tirzepatide teens versus 54.9% on placebo. They were mostly mild to moderate, and more of them came during dose increases. Vomiting, nausea and diarrhea were the most common, as the table shows.
Serious adverse events were 7.4% on tirzepatide and 3.9% on placebo. JAMA reports no deaths in either group. AJMC says 9.3% of tirzepatide teens stopped for adverse events, and no one on placebo did.
Depression or suicidal ideation was reported as an adverse event in 4.6% of tirzepatide teens and 2.0% on placebo. AJMC says none of these was serious, and every participant who reported suicidal ideation had a psychiatric history. The trial was not designed to settle that question.
What does this mean for a teen’s weight?
BMI is the number this trial measured, so the 18.5% describes BMI. The JAMA authors say the adolescent results are consistent with adult SURMOUNT-1, where about 20% weight loss was seen at 10 and 15 mg. They also compare them with the STEP TEENS trial of semaglutide 2.4 mg, which reported BMI down 16.1% at 68 weeks versus up 0.6% on placebo. For another look at reading weight-loss percentages side by side, see our wegovy pill weight loss studies piece.
Growth and puberty moved similarly in both groups over the 72 weeks, according to the researchers, and height stayed stable. They say follow-up of puberty and growth should be maintained. The trial ran from October 2023 to June 2026, per AJMC.
Who paid for the study?
Eli Lilly sponsored the trial and provided the study drug, according to JAMA. Lilly was involved in design, conduct, analysis, manuscript preparation and the decision to submit. Some of the authors are Eli Lilly employees.
Who is this study about?
The participants had a mean age of 14.6 and a mean BMI of 38.6. Their mean weight was 109.7 kg, and 61.9% were female, per AJMC. AJMC says 62% of the girls and 43% of the boys were already sexually mature at the start.
For context, AJMC cites CDC National Health and Nutrition Examination Survey data showing 22.9% of U.S. youth ages 12 to 19 had obesity from August 2021 to August 2023.
Can a 16-year-old take tirzepatide?
The trial enrolled teens aged 12 to under 18, so a 16-year-old falls in the age range it studied. Whether a 16-year-old can be prescribed tirzepatide is a decision for a pediatrician or your teen’s prescriber.
Is tirzepatide FDA-approved for teenagers?
AJMC says tirzepatide “is approved for obesity in adults.” AJMC also says the FDA has approved orlistat, liraglutide, semaglutide and phentermine-topiramate for long-term obesity treatment in adolescents. Semaglutide is sold under the brand names Wegovy, Ozempic and Rybelsus, according to a PA News story from June 29, 2024. Our plain-English guide to the difference between ozempic and wegovy explains those two names.
Common mix-ups
- 18.5% is BMI, not body weight. The study’s main measure was BMI. The body weight difference between groups was -20.1 kg, a separate number.
- 19 points is the gap, 18.5% is the change. The 18.5% is the drop on tirzepatide. The 19.0 points is the difference between tirzepatide and placebo.
- The 26% figure is from a different study. healthandpharma.net reported on December 11, 2023 that Lilly’s SURMOUNT-4 showed an average weight loss of 26.0% over 88 weeks. Per healthandpharma.net, SURMOUNT-4 measured weight in people without type 2 diabetes.
- Semaglutide results are from a different trial. The STEP TEENS figures are for semaglutide 2.4 mg, not tirzepatide.
- Some tirzepatide studies are in teens with diabetes. The ClinicalTrials.gov listing for the diabetes study lists a completed study of tirzepatide in pediatric and adolescent participants with type 2 diabetes, with 99 planned or enrolled.
- Follow-on research is still recruiting. The ClinicalTrials.gov listing for SURMOUNT-ADOLESCENTS-2 shows a recruiting study of 300 planned participants, with an extension of up to 156 more weeks of treatment for people who finish the first 72-week study.
- Weight-loss surgery is a different treatment. The NIDDK’s Teen-LABS page describes a study of surgery in teens with severe obesity, not a drug trial.
- The “growing evidence” headline is older. A PA News story dated June 29, 2024 quoted Professor Louise Baur saying there is “growing evidence” for some obesity medicines in adolescents, and that no evidence exists yet for children under 12.
- Brand name. Tirzepatide is sold under the brand name Zepbound, per healthandpharma.net’s December 11, 2023 article.
What should I ask before my teen takes any medicine?
A pediatrician is the person to ask. Bring these numbers to the appointment, and ask them to weigh the trial against your teen’s age, weight, health history and current medicines.
- Which FDA-approved teen options, if any, fit my teen’s age, weight and health history?
- What lifestyle support would come with any medicine? The tirzepatide trial paired the drug with a lifestyle intervention.
- How would growth and puberty be monitored? JAMA’s authors say follow-up of both should be maintained.
- How would nausea, vomiting or diarrhea be handled if they started?
- How would mood be checked, given the depression and suicidal ideation figures?
Key dates
- October 2023 to June 2026: the trial ran, per AJMC.
- June 29, 2024: a PA News story quoted Professor Louise Baur on “growing evidence.”
- November 15, 2026: JAMA published the trial online.
- November 17, 2026: AJMC published its summary.
- November 18, 2026: the figures on this page are current.
By Sense and Evidence Health Research Team
This article is for general information purposes only and does not constitute medical advice. Consult your doctor or qualified healthcare provider before making changes to your health routine.